A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07711418 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

DRUG: Rezpegaldesleukin
DRUG: Placebo

Sponsor

Nektar Therapeutics